Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

Fontein, D.B.Y., Seynaeve, C., Hadji, P., Hille, E.T.M., van de Water, W., Putter, H., Kranenbarg, E.M.-K., Hasenburg, A., Paridaens, R.J., Vannetzel, J.-M., Markopoulos, C., Hozumi, Y., Bartlett, J.M.S., Jones, S.E., Rea, D.W., Nortier, J.W.R., van de Velde, C.J.H., 2013.

J Clin Oncol 31, 2257–2264. doi:10.1200/JCO.2012.45.3068

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Journal of Clinical Oncology
TEAM
2013
Non-interventional study Be-1st: First line therapy with bendamustine in advanced indolent non-Hodgkin lymphoma (NHL) in treatment routine.

Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Straßl, L., 2013.

haematologica, EHA (Stockholm) 98, P321.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: Haematologica
Be-1st
2013
Lifestyle Faktoren – Einfluss auf die Lebensqualität beim Mammakarzinom.

Marschner, N., 2012.

J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Journal of Cancer Research and Clinical Oncology
TMK
2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

van de Water, W., Markopoulos, C., van de Velde, C.J.H., Seynaeve, C., Hasenburg, A., Rea, D., Putter, H., Nortier, J.W.R., de Craen, A.J.M., Hille, E.T.M., Bastiaannet, E., Hadji, P., Westendorp, R.G.J., Liefers, G.-J., Jones, S.E., 2012.

JAMA 307, 590–597. doi:10.1001/jama.2012.84

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: JAMA
TEAM
2012
EGFR mutation testing in lung cancer patients of German outpatients centres – data from the clinical TLK Registry.

Tessen, H., Groschek, M., Neise, M., Schnell, R., Kopfmann, S., Hartmann, H., 2012.

Onkologie 35 (suppl 6)(P474), 139. doi:10.1159/000258182

Abstract

Download

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Onkologie
TLK
2012
Noninterventional study HEXAFIL: analysis of G-CSF-supported chemotherapy regimens.

Tesch, H., Indorf, M., Chang, D., Ottilinger, B., 2012.

Onkologie 35 (Suppl 6)(P236), 72. doi:10.1159/000170919

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Onkologie
HEXAFIL
2012
Routine treatment of anemia in cancer patients in Germany – data from the clinical registry on anemiatherapy (TAR Registry).

Steinmetz, T., Reichert, D., Zimber, J., Hartmann, H., Vogt, M., Marschner, N., 2012.

Onkologie 35 (suppl 6)(V838), 252. doi:10.1159/000178474

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: DGHO / Journal: Onkologie
TAR
2012
Quality of life (QoL) in patients with metastatic breast cancer (MBC) treated with capecitabine – second interim analysis of the German non-interventional study (NIS).

Steffens, C., Zaiss, Lerchenmüller, C., Luhn, B., Vehling-Kaiser, U., Marschner, N., Hurst, U., Mueller, V., 2012.

J Cancer Res Clin Oncol 138(Suppl.1)(0085), 67. doi:10.1007/s00432-011-1144-4

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Journal of Cancer Research and Clinical Oncology
Xeloda-NIS
2012
MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy

Staehler, M, Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Schaller, F., Straßl, L., Junker, K., 2012.

J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4 (0327), 141–142.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DKK / Journal: Journal of Cancer Research and Clinical Oncology
MARC-2
2012
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

Staehler, MD, Bergmann, L., Grünwald, V., Huschke, T., Keilholz, U., Ohlmann, C., Stöckle, M., Weigang-Koehler, K., Hauswald, K., Schaller, F., Strassl, L., Junker, K., 2012.

J Clin Oncol 30(suppl 5; abstr 467). doi: 10.1200/jco.2012.30.5_suppl.467

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: GCS (ASCO) / Journal: Journal of Clinical Oncology
MARC-2
2012